FDA
-
-
-
-
-
-
-
EU panel backs Acadia's Rett syndrome drug trofinetide for approval
-
-
-
-
-
-
-
ACADIA Pharmaceuticals launches powder formulation of Rett syndrome drug
-
-
-
-
-
-
-
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
-
-
-
-
-
-
-
ACADIA projects $1.7 billion in 2028 sales, launches new DAYBUE formulation
-
-
-
-
-
-
-
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
-
-
-
-
-
-
-
ACADIA publishes real-world data on DAYBUE for Rett syndrome treatment
-
-
-
-
-
-
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
327,801 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

